Oral Presentation at ICKSH 2026
"Safety and Initial Efficacy Confirmed"

GC Cell announced on the 27th that it presented interim Phase 1 clinical trial results for its allogeneic umbilical cord blood-derived chimeric antigen receptor NK cell (CAR-NK) therapy, 'GCC2005,' which targets CD5, as an oral presentation at the International Congress of the Korean Society of Hematology (ICKSH 2026).


GCC2005 is one of GC Cell's key pipelines and is being developed with the goal of becoming the first-in-class therapy globally.

GC Cell Announces Interim Phase 1 Results for CD5 CAR-NK Therapy View original image

This presentation was given by Professor Yun Deokhyun of the Oncology Department at Asan Medical Center in Seoul. GCC2005 is an allogeneic CAR-NK cell therapy, in which NK cells are genetically modified to express a fourth-generation CAR that targets CD5. The therapy is designed to enhance antitumor activity and improve in vivo persistence. Currently, a domestic Phase 1 clinical trial is underway for patients with relapsed or refractory NK and T cell lymphomas. These diseases are considered difficult-to-treat areas with very limited treatment options and poor prognoses, resulting in a high unmet need for new therapies.


According to the interim analysis, safety and initial efficacy have been confirmed in the group of patients with refractory disease, and no serious adverse events or major toxicities have been reported. The objective response rate (ORR) was 62.5%. In some patients (37.5%), complete remission (CR) was also observed, demonstrating the therapy's potential efficacy. The presentation also included a case in which a T cell lymphoma patient who had experienced multiple relapses maintained complete remission for more than 12 months after treatment.


GC Cell is currently conducting a dose-escalation study for the high-dose cohort and plans to expand development to domestic Phase 1b and global Phase 2 clinical trials in the future.



GC Cell CEO Won Seongyong stated, "We are continuously presenting GCC2005's clinical data at global conferences, enabling us to engage in in-depth discussions on the clinical significance with medical professionals and researchers. We will continue to advance high-dose cohort evaluations and follow-up clinical trials without delay."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing